Switzerland plans new support for people with rare diseases

More than 500,000 people in Switzerland may be living with a rare disease, according to government estimates. The figure is driving a new federal effort to strengthen specialised care, advice and information for patients and families who often move between medical services in search of answers.

The Swiss government announced on September 2, 2026, that it plans to create two laws rather than pursue a single piece of legislation. The first would establish the legal basis for financial support for specialised care structures and information and advisory services. That could include the networks and organisations that help patients navigate diagnosis, treatment and long term care.

The initiative follows years of political pressure. Parliament instructed the government in 2022 to create a legal framework for measures set out in Switzerland’s national rare diseases strategy, adopted in 2014. The government submitted a bill for consultation a year ago, while also signalling that it wanted to support care networks in future.

For patients, the immediate significance lies in a clearer federal role and a potential funding mechanism. The second law, covering a national register, will take longer to prepare.

The first law would put specialised care and advice on a firmer legal footing. The government has not yet set out a final list of services or funding levels, but its stated objective is to support specialised care structures and information and advisory services across the country.

Rare diseases can require expertise spread across hospitals, outpatient clinics, laboratories and patient organisations. A coordinated network can help families find the right specialists and reduce the risk of fragmented care. The government’s announcement places those structures within the scope of future federal support.

The proposal also reflects Switzerland’s federal healthcare landscape. Patients may rely on cantonal hospitals, university centres and national organisations, while financing and responsibilities are divided among different institutions. A federal legal basis could make it easier to sustain services that serve relatively small patient groups but require highly specialised knowledge.

The plan remains at an early stage. The announcement describes the intended framework, not a completed financing model. The government must still develop the legislation and work through the parliamentary process. Consultation responses will shape that work, particularly on how services should connect across cantons and how digital systems can support patients without duplicating existing structures.

A national register is not expected before early 2030 at the earliest. The Federal Department of Home Affairs, known as the EDI, has received a mandate to submit a draft bill for the register as a second legislative step.

The government separated the register from the funding law because the data project must be coordinated with the digital transformation of Swiss healthcare. In particular, officials want the work aligned with the Digisanté programme. Feedback from the consultation process identified a need to capture shared digital infrastructure, avoid duplicated processes and control costs.

The proposed register would improve Switzerland’s information base on rare diseases and make research easier. Better data could help researchers identify patient groups, understand how conditions affect people in Switzerland and assess where specialist services are needed. It could also give policymakers a clearer picture of demand across the country.

The register will raise practical questions about data governance, interoperability and patient privacy. The government announcement does not provide the final design or operating rules. Those details will emerge through the draft bill and subsequent parliamentary debate. Until then, the register remains a planned instrument rather than an operating service.

Between 7,000 and 8,000 rare diseases have been described worldwide, according to the government. The category includes conditions such as cystic fibrosis and Pompe disease, but the diseases differ widely in symptoms, progression and treatment.

Swiss policy defines a rare disease as one affecting no more than 5 people in 10,000 and causing a life threatening or chronically debilitating condition. The low prevalence of each individual disease can make diagnosis difficult, even when the combined number of affected people is large.

Half of all rare diseases manifest in childhood. Around 80% are estimated to have a genetic cause. For families, the search for a diagnosis can therefore involve paediatricians, genetic specialists, laboratories and hospital teams. A child’s care may continue across several stages of life and multiple institutions.

Most rare diseases currently have no cure. Treatment focuses on easing symptoms and improving quality of life, according to the government. That makes access to reliable advice, specialist coordination and continuing care central to the proposed reforms. Support may also help families understand available therapies and connect with research projects, although the planned legislation does not itself promise new treatments.

The next milestone is legislative, not clinical: a draft register bill in early 2030 at the earliest. Before then, the government must advance the law on specialised care and advice, integrate consultation feedback and clarify how responsibilities will be shared between federal and cantonal bodies.

The timetable reflects the technical challenge of connecting rare disease policy with the wider Digisanté programme. Officials say coordination can create synergies, prevent duplicated digital processes and infrastructure, and reduce costs. Those goals will matter as Switzerland builds systems intended to serve patients whose conditions are individually uncommon but collectively affect more than half a million people.

Parliament’s 2022 instruction gave the government a formal mandate, building on the national strategy adopted in 2014. The latest decision moves that strategy toward a new legal phase, while keeping the register on a separate track.

For patients and families, progress will be measured in practical terms: whether specialised services are easier to find, whether advice is available across cantonal borders and whether research can draw on better data. The government has now set the direction. The legislation will determine how far the support reaches.